Structure via PubChem · Public domain (PubChem)
كابرجولين
Sign in to saveAlso known as Cabaser®, Caberlin®, (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea, 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea, (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide, (8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
مركب كيميائي
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 477165198
- Drug.image
- Cabergoline Skeletal.png
- Drug.image_class
- skin-invert-image
- Drug.width
- 268
- Drug.image2
- Cabergoline_3D_Xtal_ballandstick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 260
- Drug.tradename
- Dostinex, others
- Drug.DailyMedID
- Cabergoline
- Drug.routes_of_administration
- Oral
- Drug.ATC_prefix
- G02
- Drug.ATC_suffix
- CB03
- Drug.legal_AU
- S4
- Drug.legal_US
- Rx-only
- Drug.bioavailability
- 50–80%
- Drug.protein_bound
- Moderately bound (40–42%); concentration-independent
via Wikipedia infobox
Chemical data
- Formula
- C26H37N5O2
- Molecular weight
- 451.6 g/mol
- IUPAC name
- (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
- SMILES
- CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
- InChIKey
- KORNTPPJEAJQIU-KJXAQDMKSA-N
- XLogP
- 3.4
- Polar surface area
- 71.7 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1996
- Admin. routes
- oral
- Indications
- infertility, restless legs syndrome, cocaine dependence, obesity
via ChEMBL · EBI
Research
2,371 papers- Cabergoline in acromegaly.Pituitary · 2017
- Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial.Obstetrics and gynecology · 2023
- Cabergoline Use and Pregnancy Outcomes: A Systematic Review.Birth defects research · 2025
- Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.Journal of the International AIDS Society · 2019
- Pituitary acting drugs: cabergoline and pasireotide.Pituitary · 2022
via PubMed
Wikidata facts
- Mass
- 451.294725
- Has use
- medication
Show 8 more facts
- chemical formula
- C₂₆H₃₇N₅O₂
- canonical SMILES
- CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
- isomeric SMILES
- CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
- World Health Organisation international non-proprietary name
- cabergoline
- defined daily dose
- 0.5
- subject has role
- antineoplastic
- significant drug interaction
- chlorpromazine
- Commons category
- Cabergoline
via Wikidata · CC0
Article · العربية
كابرجولين (الأسماء التجارية Caberlin, Dostinex and Cabaser)، من مشتقات فطر الارغوت، وهو ناهض قوي يعمل على مستقبلات الدوبامين D2. وقد بينت الدراسات على الفئران أنالكابرجولين له تأثيرمباشر مثبط على خلايا لاكتوتروف الموجودة بالغدة النخامية (البرولاكتين). وكثيراً ما يستخدم كخط العلاج الأول لأورام الغدة النخامية التي تفرزالبرولاكتين (البرولاكتينوماس) بسبب قوة التجاذب بينه وبين مستقبلات D2 وأيضاً قلة حدة آثارها الجانبية وملاءمة جدول الجرعات مقارنة بالبروموكريبتين الذي كان يستخدم سابقاً.
Abstract from DBpedia / Wikipedia · CC BY-SA